News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,100 Results
Type
Article (42699)
Company Profile (439)
Press Release (677961)
Multimedia
Podcasts (91)
Webinars (16)
Section
Business (208887)
Career Advice (2025)
Deals (36047)
Drug Delivery (105)
Drug Development (83692)
Employer Resources (173)
FDA (16514)
Job Trends (15132)
News (353182)
Policy (33155)
Tag
Academia (2645)
Accelerated approval (12)
Adcomms (26)
Allergies (98)
Alliances (51105)
ALS (115)
Alzheimer's disease (1503)
Antibody-drug conjugate (ADC) (168)
Approvals (16492)
Artificial intelligence (331)
Autoimmune disease (33)
Automation (19)
Bankruptcy (373)
Best Places to Work (11841)
BIOSECURE Act (19)
Biosimilars (124)
Biotechnology (331)
Bladder cancer (99)
Brain cancer (36)
Breast cancer (377)
Cancer (2970)
Cardiovascular disease (227)
Career advice (1695)
Career pathing (30)
CAR-T (194)
CDC (32)
Cell therapy (527)
Cervical cancer (22)
Clinical research (68702)
Collaboration (1071)
Company closure (3)
Compensation (703)
Complete response letters (28)
COVID-19 (2686)
CRISPR (65)
C-suite (344)
Cystic fibrosis (119)
Data (3064)
Decentralized trials (2)
Denatured (31)
Depression (71)
Diabetes (351)
Diagnostics (6486)
Digital health (24)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (147)
Drug pricing (131)
Drug shortages (29)
Duchenne muscular dystrophy (137)
Earnings (88727)
Editorial (44)
Employer branding (21)
Employer resources (149)
Events (117380)
Executive appointments (874)
FDA (18204)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (977)
Gene editing (143)
Generative AI (23)
Gene therapy (407)
GLP-1 (826)
Government (4595)
Grass and pollen (4)
Guidances (182)
Healthcare (19172)
HIV (42)
Huntington's disease (31)
IgA nephropathy (43)
Immunology and inflammation (164)
Immuno-oncology (9)
Indications (40)
Infectious disease (2862)
Inflammatory bowel disease (156)
Inflation Reduction Act (13)
Influenza (64)
Intellectual property (122)
Interviews (312)
IPO (16875)
IRA (48)
Job creations (3708)
Job search strategy (1436)
Kidney cancer (13)
Labor market (53)
Layoffs (528)
Leadership (20)
Legal (8006)
Liver cancer (80)
Longevity (11)
Lung cancer (416)
Lymphoma (212)
Machine learning (11)
Management (58)
Manufacturing (402)
MASH (95)
Medical device (13616)
Medtech (13621)
Mergers & acquisitions (19894)
Metabolic disorders (888)
Multiple sclerosis (99)
NASH (19)
Neurodegenerative disease (132)
Neuropsychiatric disorders (39)
Neuroscience (2224)
NextGen: Class of 2025 (6759)
Non-profit (4558)
Now hiring (48)
Obesity (452)
Opinion (237)
Ovarian cancer (103)
Pain (113)
Pancreatic cancer (123)
Parkinson's disease (193)
Partnered (22)
Patents (306)
Patient recruitment (171)
Peanut (51)
People (59101)
Pharmaceutical (86)
Pharmacy benefit managers (22)
Phase I (21595)
Phase II (30319)
Phase III (22391)
Pipeline (1672)
Policy (214)
Postmarket research (2601)
Preclinical (9276)
Press Release (67)
Prostate cancer (146)
Psychedelics (44)
Radiopharmaceuticals (272)
Rare diseases (492)
Real estate (6025)
Recruiting (67)
Regulatory (23124)
Reports (50)
Research institute (2422)
Resumes & cover letters (352)
Rett syndrome (9)
RNA editing (10)
RSV (49)
Schizophrenia (94)
Series A (169)
Series B (116)
Service/supplier (11)
Sickle cell disease (66)
Special edition (21)
Spinal muscular atrophy (153)
Sponsored (33)
Startups (3776)
State (2)
Stomach cancer (15)
Supply chain (77)
Tariffs (58)
The Weekly (58)
Vaccines (802)
Venture capital (56)
Weight loss (278)
Women's health (49)
Worklife (17)
Date
Today (91)
Last 7 days (380)
Last 30 days (1865)
Last 365 days (32003)
2025 (17382)
2024 (36302)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (738)
Alabama (67)
Alaska (7)
Arizona (252)
Arkansas (14)
Asia (39661)
Australia (6581)
California (7615)
Canada (2384)
China (696)
Colorado (328)
Connecticut (334)
Delaware (195)
Europe (86736)
Florida (1129)
Georgia (249)
Hawaii (1)
Idaho (59)
Illinois (663)
India (27)
Indiana (365)
Iowa (19)
Japan (232)
Kansas (112)
Kentucky (30)
Louisiana (15)
Maine (64)
Maryland (1049)
Massachusetts (5765)
Michigan (248)
Minnesota (461)
Mississippi (3)
Missouri (91)
Montana (30)
Nebraska (25)
Nevada (81)
New Hampshire (70)
New Jersey (2127)
New Mexico (30)
New York (2124)
North Carolina (1153)
North Dakota (9)
Northern California (3324)
Ohio (240)
Oklahoma (16)
Oregon (38)
Pennsylvania (1635)
Puerto Rico (17)
Rhode Island (37)
South America (1112)
South Carolina (34)
South Dakota (1)
Southern California (2842)
Tennessee (126)
Texas (1150)
United States (28350)
Utah (223)
Virginia (193)
Washington D.C. (74)
Washington State (660)
West Virginia (4)
Wisconsin (70)
721,100 Results for "alaunos therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering
June 23, 2025
·
3 min read
Business
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the third quarter ended September 30, 2023.
November 14, 2023
·
9 min read
Business
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives
Alaunos Therapeutics, Inc., announced financial results for the second quarter ended June 30, 2023.
August 14, 2023
·
8 min read
Lone Star Bio
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be participating in the following upcoming investor conferences.
March 29, 2023
·
1 min read
Lone Star Bio
Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies
Alaunos Therapeutics, Inc. today announced that the Company will present at the 2nd Hawaii Global Summit on Thoracic Malignancies taking place June 27 – July 1, 2023.
June 29, 2023
·
2 min read
Business
Alaunos Therapeutics Reports First Quarter 2023 Financial Results
Alaunos Therapeutics, Inc., a leading T-cell receptor cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, announced financial results for the first quarter ended March 31, 2023, and provided a corporate update.
May 10, 2023
·
9 min read
Press Releases
UTILITY Therapeutics Announces Acquisition by Alembic Pharmaceuticals Inc.
July 3, 2025
·
7 min read
Business
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a corporate update.
March 7, 2023
·
12 min read
Business
Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023
Alaunos Therapeutics, Inc. today announced that it will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, before the open of U.S. markets.
May 3, 2023
·
1 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
1 of 72,110
Next
